Comparison · NCT01401465-deb31956
Ciclesonide vs Mometasone: The Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ciclesonide vs Mometasone: The Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation. Trial comparisons, record NCT01401465-deb31956. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01401465-deb31956
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0193 | 0.00887 | 0.0414 | wilson | |
| Risk in group 2 | 0.0128 | 0.005 | 0.0325 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00647 | -0.0158 | 0.03 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 0.429 | 5.28 | log | |
| Odds ratio, group 1 over group 2 | 1.51 | 0.423 | 5.42 | log | |
| Number needed to treat, for one more participant with the outcome on Ciclesonide than on Mometasone | 155 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ciclesonide | Ciclesonide nasal aerosol 74 mcg | 6 | 311 | OG000 |
| Group 2 | Mometasone | Mometasone AQ 200 mcg | 4 | 312 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation
- Description
- Time frame
- Over both two-week treatment periods combined
- Population
- ITT
Source ClinicalTrials.gov
Trial
- Title
- Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
- NCT number
- NCT01401465
- Phases
- PHASE3
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- ciclesonide, mometasone
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Results first posted
- 2013-04-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01401465?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01401465-deb31956